Respiratory & Immunology皇冠官网平台

皇冠注册官网地址

皇冠注册官网地址

皇冠注册官网地址


皇冠注册官网地址

皇冠官网平台




皇冠官网平台


皇冠官网平台


皇冠官网平台


皇冠注册官网地址

Phase III/Reg. refers to assets that are in Phase III or that have been submitted for regulatory approval and may include assets that are now launched in one or more major markets.


皇冠注册官网地址

Phase I

皇冠官网平台

  • AZD0284 psoriasis/respiratory
  • AZD0449 asthma
  • AZD1402 asthma
  • AZD5634 cystic fibrosis
  • AZD8154 asthma
  • MEDI5117 China rheumatoid arthritis

Phase II

皇冠官网平台

  • abediterol asthma/chronic obstructive pulmonary disease
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • AZD7986 chronic obstructive pulmonary disease
  • AZD9567 rheumatoid arthritis/respiratory
  • MEDI3506 chronic obstructive pulmonary disease and atopic dermatitis
  • navafenterol (AZD8871) chronic obstructive pulmonary disease
  • tezepelumab atopic dermatitis
  • tezepelumab chronic obstructive pulmonary disease
  • velsecorat (AZD7594) asthma/chronic obstructive pulmonary disease

Phase III

皇冠官网平台

  • anifrolumab TULIP systemic lupus erythematosus
  • Bevespi Aerosphere (PT003) chronic obstructive pulmonary disease
  • Breztri Aerosphere (PT010) chronic obstructive pulmonary disease
  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE severe uncontrolled asthma
  • nirsevimab passive RSV immunisation
  • PT027 asthma
  • tezepelumab NAVIGATOR SOURCE severe uncontrolled asthma

LCM Projects

皇冠官网平台

  • Breztri (PT010) asthma
  • Duaklir Genuair chronic obstructive pulmonary disease
  • Fasenra MANDARA eosinophilic granulomatosis with polyangiitis
  • Fasenra OSTRO ORCHID (Japan/China) nasal polyposis
  • Fasenra RESOLUTE chronic obstructive pulmonary disease
  • Symbicort SYGMA as-needed use in mild asthma



皇冠官网平台


皇冠注册官网地址

皇冠官网平台


Accolate, Accoleit, Vanticon皇冠官网平台

zafirlukast

Bevespi Aerosphere皇冠官网平台

glycopyrronium/formoterol fumarate

Breztri Aerosphere皇冠官网平台

budesonide/glycopyrronium/formoterol fumarate

Bricanyl Respules皇冠官网平台

terbutaline

Bricanyl Turbuhaler皇冠官网平台

terbutaline in a dry powder inhaler

Daliresp/Daxas皇冠官网平台

roflumilast

Duaklir Genuair皇冠官网平台

aclidinium/formoterol

Eklira Genuair/Tudorza/Bretaris皇冠官网平台

aclidinium, a LAMA

Fasenra皇冠官网平台

benralizumab

Oxis Turbuhaler皇冠官网平台

Oxis Turbuhaler

Pulmicort Respules皇冠官网平台

budesonide inhalation suspension

Pulmicort Turbuhaler皇冠官网平台

budesonide

Rhinocort皇冠官网平台

budesonide

Symbicort pMDI皇冠官网平台

budesonide/formoterol

Symbicort Turbuhaler皇冠官网平台

budesonide/formoterol


皇冠官网平台



Veeva ID: Z4-23796

Date of next review: April 2022